Curis (CRIS) Financials: History & Chart

Curis, Inc.(CRIS)

Biotechnology · Lexington, MA

$0.76-0.03 (-3.57%)

Delayed quote: Oct 6, 2026, 11:00 AM EDT

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Lexington, MA

22 employees

www.curis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James Dentzer

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	4.31M	0.00	0.00	1.14M	3.18M	2.75M	2.38M	3.35M	2.93M
Cost of Goods Sold	31K	8K	8K	0.00	15K	16K	14K	17K	22K
Gross Profit	4.28M	-8K	-8K	1.14M	3.16M	2.73M	2.37M	3.33M	2.91M
Gross Profit Margin	99.3%	N/A	N/A	100.0%	99.5%	99.4%	99.4%	99.5%	99.2%
Total Operating Expenses	40.24M	9.93M	11.51M	8.71M	10.09M	10.98M	12.52M	12.32M	13.48M
Research & Development	25.42M	6.71M	6.45M	5.83M	6.43M	7.46M	8.54M	8.97M	9.72M
Selling, General & Administrative	14.82M	3.22M	5.06M	2.88M	3.65M	3.53M	3.98M	3.35M	3.75M
Operating Income (EBIT)	-35.95M	-9.94M	-11.52M	-7.57M	-6.92M	-8.25M	-10.16M	-8.99M	-10.57M
Operating Margin	-833.4%	N/A	N/A	-665.2%	-218.0%	-300.1%	-426.8%	-268.9%	-360.5%
Income Before Tax (EBT)	-21.15M	-8.58M	-24.20M	19.36M	-7.73M	-8.59M	-10.62M	-9.62M	-10.09M
Interest Income	270K	62K	77K	51K	80K	92K	93K	227K	325K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	615K	N/A
Other Income/Expense	14.80M	1.36M	-12.68M	26.93M	-805K	-342K	-459K	-624K	475K
Net Income	-21.15M	-8.58M	-24.20M	19.36M	-7.73M	-8.59M	-10.62M	-9.62M	-10.09M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-490.3%	N/A	N/A	1700.9%	-243.4%	-312.6%	-446.1%	-287.5%	-344.3%
EBITDA	-35.86M	-9.93M	-11.51M	-7.53M	-6.88M	-8.21M	-10.10M	-8.98M	-10.51M
EBITDA Margin	-831.2%	N/A	N/A	-662.0%	-216.7%	-298.6%	-424.3%	-268.4%	-358.4%
Depreciation & Amortization	94K	8K	8K	36K	42K	42K	59K	16K	61K
EPS Basic	-14.22	-4.02	-25.00	24.60	-9.80	-13.60	-25.00	-25.00	-34.00
EPS Diluted	-14.22	-4.02	-25.00	24.60	-9.80	-13.60	-25.00	-25.00	-34.00
Weighted Average Basic Shares	2.14M	2.14M	968K	787K	784K	631K	425K	384K	297K
Weighted Average Diluted Shares	2.14M	2.14M	968K	787K	784K	631K	425K	384K	297K

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	9.44M	10.91M	10.02M	10.16M	10.65M	10.84M	10.00M	10.43M
Cost of Goods Sold	45K	98K	212K	257K	533K	534K	503K	563K
Gross Profit	9.40M	10.81M	9.81M	9.90M	10.12M	10.30M	9.50M	9.87M
Gross Profit Margin	99.5%	99.1%	97.9%	97.5%	95.0%	95.1%	95.0%	94.6%
Total Operating Expenses	42.34M	55.35M	58.14M	62.92M	52.18M	35.20M	33.86M	39.20M
Research & Development	28.25M	38.56M	39.50M	43.28M	34.88M	23.07M	22.30M	24.41M
Selling, General & Administrative	14.05M	16.79M	18.65M	19.65M	17.30M	12.13M	11.55M	14.79M
Operating Income (EBIT)	-32.90M	-44.54M	-48.33M	-53.02M	-42.06M	-24.90M	-24.36M	-29.33M
Operating Margin	-348.4%	-408.3%	-482.2%	-521.7%	-395.0%	-229.8%	-243.5%	-281.3%
Income Before Tax (EBT)	-7.58M	-43.39M	-47.41M	-56.67M	-45.44M	-29.91M	-32.14M	-32.58M
Interest Income	316K	1.77M	2.94M	1.12M	211K	63K	614K	684K
Interest Expense	2.19M	615K	2.02M	4.77M	4.47M	5.09M	4.85M	3.93M
Other Income/Expense	25.32M	1.15M	919K	-3.65M	-3.37M	-5.01M	-7.79M	-3.24M
Net Income	-7.58M	-43.39M	-47.41M	-56.67M	-45.44M	-29.91M	-32.14M	-32.58M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-80.3%	-397.8%	-473.0%	-557.7%	-426.7%	-276.0%	-321.3%	-312.4%
EBITDA	-32.73M	-44.34M	-48.08M	-52.79M	-41.91M	-24.75M	-24.23M	-29.16M
EBITDA Margin	-346.6%	-406.5%	-479.7%	-519.5%	-393.5%	-228.5%	-242.2%	-279.6%
Depreciation & Amortization	169K	203K	255K	233K	158K	144K	125K	177K
EPS Basic	-11.60	-137.60	-179.20	-242.80	-198.40	-245.80	-387.40	-393.40
EPS Diluted	-11.60	-137.60	-179.20	-242.80	-198.40	-245.80	-387.40	-393.40
Weighted Average Basic Shares	658K	315K	265K	233K	229K	122K	83K	83K
Weighted Average Diluted Shares	658K	315K	265K	233K	229K	122K	83K	83K

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.